Fluidigm, which makes high-throughput sequencing devices for genetic labs, filed on Friday with the SEC to raise up to $86 million in an initial public offering. The South San Francisco, CA-based company, which was founded in 1999 and booked $31 million in sales for the 12 months ended September 30, plans to list on the NASDAQ under the symbol FLDM. Fluidigm had previously attempted to offer 5.3 million shares at a range of $14-$16 in its September 2008 IPO before postponing the deal due to market conditions. Deutsche Bank Securities and Piper Jaffray are the lead underwriters on the deal, for which pricing terms and timing were not disclosed.
